Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
about
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort studyA Guide to Non-Alcoholic Fatty Liver Disease in Childhood and AdolescenceThe adipokine/ceramide axis: key aspects of insulin sensitizationA Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease.Increasing fatty acid oxidation remodels the hypothalamic neurometabolome to mitigate stress and inflammationUrinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver diseaseThe role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesisTranslational approaches: from fatty liver to non-alcoholic steatohepatitis.Expression of fatty acid synthase in nonalcoholic fatty liver disease.Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass.Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice.Reducing Liver Fat by Low Carbohydrate Caloric Restriction Targets Hepatic Glucose Production in Non-Diabetic Obese Adults with Non-Alcoholic Fatty Liver DiseaseSerum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese menPharmacological glycerol-3-phosphate acyltransferase inhibition decreases food intake and adiposity and increases insulin sensitivity in diet-induced obesity.Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice.P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis.Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly.Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling2-(3-Benzoylthioureido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ameliorates metabolic disorders in high-fat diet-fed mice.Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine.Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patientsNon-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis.Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis.Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity.Role of ceramides in nonalcoholic fatty liver diseaseQuantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in miceNuclear receptors reverse McGarry's vicious cycle to insulin resistance.TFE3 Alleviates Hepatic Steatosis through Autophagy-Induced Lipophagy and PGC1α-Mediated Fatty Acid β-Oxidation.Combined ethanol extract of grape pomace and omija fruit ameliorates adipogenesis, hepatic steatosis, and inflammation in diet-induced obese mice.Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart diseaseNon alcoholic fatty liver disease and metabolic syndrome.Changes of liver fat content and transaminases in obese children after 12-mo nutritional intervention.Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population.SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagyLow serum triglyceride levels as predictors of cardiac death in heart failure patients.CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).
P2860
Q24596256-1BD31655-A5FC-4780-B43F-B6D1D1E265B8Q26744488-B0092D0A-B4FE-4F85-B03D-886951844102Q27025041-9C052AD9-AAE7-4290-998C-63736D7D9276Q28074377-3FBD7EB9-63CF-466D-BE41-3415D5AD3829Q28542870-1EE3FF77-DC50-4FE3-87AC-CB7346FE1FE6Q33599564-475B3FCC-7DF6-4613-BC7D-7DD6ACB045A4Q33864337-ACE29DBA-B6F3-424E-81DE-A9718061E5E4Q33886918-11A2F3B6-910D-4FB9-A812-5BA3B4D65544Q33958697-7215E202-313F-4ABC-A9B0-3A48D72C4BACQ33962008-176D942B-0186-4138-847B-0AAE8C970614Q34037347-38D8844D-B8CC-4FFF-AA5D-5141B044D6F1Q34171384-EE49707A-E529-4DC1-8EFB-D32551B32895Q34212126-2B079DF6-24ED-4351-9372-A7A4A6B3E4D1Q34522557-8EA81052-5ABE-4211-9B8C-24EACC4BA634Q34917717-AAEC1536-581F-4B63-B9A5-ED773BE35BE7Q35086922-4753619A-EDE7-452C-A47D-73DE3A0E5AF6Q35152196-9DAD32BA-3394-4A34-A71C-307ED2579B4CQ35178036-6ADD73B5-4D19-4BAB-9B6E-11AF990E0671Q35209849-4AE89EDF-B4DC-4624-B818-4ECD67B46AB2Q35235426-18AD7536-B8E2-43AF-A312-A8A4CC63E1B9Q35289357-9BE28744-8989-41A1-B17F-3C8375647145Q35474502-57951575-A503-4885-87CB-D05664668A49Q35661889-69B41F2B-77D5-48A7-AC11-81170898CD46Q35839709-784051D1-F6FE-41DC-B4FF-DEF929F4EA15Q35989623-003518A4-FB11-49B2-8D19-B662DB2CBC6EQ36024871-5CFFAC02-9FB6-437E-9955-3591DFCD08D3Q36076151-41DDF075-0CE2-447F-AB34-ED54A04294A8Q36129432-74F0B7F2-593A-4851-9196-F205807EF7C0Q36298345-FD863695-6FD1-4C8B-B3C8-7BA40D95452FQ36722534-C459BC42-5675-42F6-944B-4812B8D8F4E0Q36732028-1E2551F8-2A11-4860-8C28-FDD1DD58523BQ36743724-74C26A82-FE71-4A26-B66A-65D9A98CD31CQ36838159-56665923-052E-44CC-9575-9B745902BD1FQ37002532-898076FC-2708-4FB7-AC51-0991274884F1Q37078311-C8B808F1-D3DB-4DBC-8498-A902EB6EF617Q37196525-DDD9F8DB-CAD8-4648-BBBA-EBEFEE021983Q37283588-5984A91F-14F5-41EF-9A66-DBD5283EC9F5Q37355532-9F043426-0F4F-4ACE-9301-7720EA33433AQ37370010-A4C91C71-2C0D-46F4-80C6-CF741EAB40F1Q37624585-3B6FB894-0967-419C-B248-52A1DACB1A45
P2860
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@en
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@nl
type
label
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@en
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@nl
prefLabel
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@en
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@nl
P1476
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
@en
P2093
Anna Mae Diehl
Steve S Choi
P304
P356
10.1097/MOL.0B013E3282FF5E55
P577
2008-06-01T00:00:00Z